Zymogenetics, Inc.

Other

Novo Nordisk A/s

Osteoscreen, Inc.

Osteoscreen Ip, LLC

Robert R West

Patricia A McKernan

Virender M Labroo

Theresa Martinez

Shirley R Gasper

Nand Baindur

Kirk G Robbins

Gregory R Mundy

James R Piggott

Paul O Sheppard

Robert A Smith

Paul D Bishop

Charles E Hart

Brian A Fox

Jeffrey Van Ness

Charles R Petrie

Katherine E Lewis

Penny Thompson

Richard M Garcia

Annemarie Reinhardt Varming

Birgitte Ro Rassing

Colin Lellis

Lennie Chen

Oliver J McConnell

Teresa Martinez

Hank R Franklin

A wind turbine system to provide electrical power in areas not connected to the electrical power grid. The wind turbine system includes a frame and a rotatable shaft supported by the frame. A ring and idler gear assembly is coupled to the rotatable shaft. An upper rotor assembly is coupled to the rotatable shaft. The upper rotor assembly is configured to rotate in a first direction and thereby to rotate the rotatable shaft in a first direction. A lower rotor assembly is coupled to the ring and idler gear assembly. The lower rotor assembly is configured to rotate in a second direction which is opposite of the first direction and thereby to rotate the rotatable shaft in the first direction via the ring and idler gear assembly.

Wind turbine system

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

Methods of modulating gastrointestinal contractility

The topical administration of statins for the treatment of bone disorders is disclosed.

Topical administration of statins for treatment of bone disorders

The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such moieties, which can be used to treat conditions characterized by inappropriate complement activation.

Peptide and polypeptide inhibitors of complement C1s

Isoprenoid pathway inhibitors for stimulating bone growth

Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C; Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optionally be fused; and R' represents a cation, H or a substituted or unsubstituted alkyl group of 1-6 C; and the dotted lines represent optional .pi.-bonds, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. These compounds can be used in combination with other bone growth-promoting compounds and/or estrogens and/or bisphosphonates for this purpose.

Compositions and methods for stimulating bone growth

Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;

A compound that is useful for inhibiting FXIIIa catalysis of fibrin cross-linking, and related pharmaceutical compositions and methods, are disclosed. The compound and compositions may be advantageously used to enhance fibrinolysis and resolution of blood clots.

Factor XIIIA inhibitor

The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.

Native calcitonin mimetics

Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response pathway. The glucagon antagonists may be used within therapeutic compositions to treat disease states associate with elevated glucose levels, including diabetes and hyperglycemia. The present invention also discloses a biologically pure culture of ATCC accession number 74200, as well as methods relating to the production of glucagon antagonists by cultivating the same in a nutrient medium and recovering the glucagon antagonist therefrom.

Method for inhibiting the stimulation of a glucagon-induced response

Methods for inhibiting intimal hyperplasia in the vasculature of mammals, including primates, are disclosed. The methods comprise administering to the mammal an effective amount of Brefeldin A or a derivative of Brefeldin A. The methods are useful in reducing intimal hyperplasia due to, for example, vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft. The non-peptide PDGF antagonists Brefeldin A and its derivatives may optionally be administered coordinately with heparin, whereby the coordinately administered of non-peptide PDGF antagonist and heparin are combinatorially effective in inhibiting intimal hyperplasia.

PDGF antagonists III

Compounds that selectively modulate the remodeling pathway of platelet activating factor (PAF) are described. Related pharmaceutical compositions and methods are also disclosed. These compounds, pharmaceutical compositions and methods are useful for reducing or eliminating inflammation.

Growing community of inventors

Seattle, WA, United States of America

Robert R West